Modelling dependent censoring in time-to-event data using boosting copula regression.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: colon cancer
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The data has a high proportion of right-censored observations without information on the cause of censoring. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s10985-025-09674-x.
[UNLABELLED] Survival analysis plays a pivotal role across disciplines, including engineering, economics, and social sciences—not just in biomedical research.
APA
Strömer A, Klein N, et al. (2025). Modelling dependent censoring in time-to-event data using boosting copula regression.. Lifetime data analysis, 31(4), 994-1016. https://doi.org/10.1007/s10985-025-09674-x
MLA
Strömer A, et al.. "Modelling dependent censoring in time-to-event data using boosting copula regression.." Lifetime data analysis, vol. 31, no. 4, 2025, pp. 994-1016.
PMID
41118109 ↗
Abstract 한글 요약
[UNLABELLED] Survival analysis plays a pivotal role across disciplines, including engineering, economics, and social sciences—not just in biomedical research. In many of these applications, incomplete observations due to censoring are common, arising from limited follow-up periods, study dropouts, or administrative constraints. A standard assumption in such settings is that the censoring mechanism is independent of the survival process. This assumption primarily holds when censoring occurs at the end of the observation period. However, there may be dependence between event and censoring times. For example, if a patient’s health deteriorates and they withdraw due to poor prognosis, the time of censoring depends on their health status, leading to dependent censoring as sicker patients are censored earlier. To address such situations adequately in statistical analyses, we propose a model-based boosting approach using distributional copula regression. Our approach models the joint distribution of survival and censoring times by linking unknown marginal distributions through an unknown parametric copula. All distribution parameters of the resulting joint distribution are estimated simultaneously as functions of potentially different covariates. A key merit of the boosting approach is its data-driven variable selection, which is particularly important for such flexible models. Estimation remains feasible even for high-dimensional data with more covariates than observations, where classical estimation frameworks meet their limits. To investigate the performance of our method, we conduct a comprehensive simulation study, and demonstrate its practical application using a recent observational study analyzing the overall survival of patients with colon cancer. The data has a high proportion of right-censored observations without information on the cause of censoring.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s10985-025-09674-x.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s10985-025-09674-x.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Predicting progression-free survival in hormone-receptor positive (HR+/HER2-) metastatic breast cancer (MBC) treated with CDK4/6 inhibitors: A machine learning approach.
- Pharmacologic synergy versus independent action in androgen receptor-axis-targeted agent-docetaxel triplet therapy for metastatic hormone-sensitive prostate cancer: a copula-based analysis.
- Advanced deep learning framework for breast cancer detection using digital breast tomosynthesis images.
- Interpretable machine-learning prediction of severe myelosuppression in colorectal cancer patients receiving chemotherapy using XGBoost and SHAP: a retrospective study with a web-based calculator.
- A machine learning framework predicts oncogenic driver mutations from SNP profiles in lung adenocarcinoma.
- Development and validation of an interpretable machine learning model for predicting Gleason score upgrade in prostate cancer.